Throughout the back and forth about the TPPA, one of the biggest concerns has been how the deal could affect Kiwis' access to medicines. The worry was that drug companies would invent new treatments but be allowed to keep the recipe to themselves for many years. That would prevent competition and allow them to keep prices much higher. This page looks at how the TPPA will affect your prescriptions bill and access to medicines, as well as the global impact on affordable medicine.
WHAT WE GET UNDER TPPA:
➜ Principles for increased transparency and fairness in national pharmaceutical purchasing were agreed to by all TPPA parties (but those principles are not legally enforceable).
AND WHAT WE GIVE UP:
➜ A requirement to provide patent extensions when there are delays in approving medicines.
➜ A new review mechanism for pharmaceutical companies to challenge PHARMAC's decisions.
➜ Patent extensions will cost about $1 million a year, while setting up up the PHARMAC review process will cost $4.5 million upfront with $2.2million a year in ongoing costs
➜ Global expanded market access for Big Pharma at monopoly prices dictated by industry. This will hit less developed countries hardest.
When doctors speak out, we should probably listen
(They are rather qualified after all...)
"TPPA will bring stagnation on actions to control the products that make people sick in the first place - tobacco control, managing junk food advertising to children and cutting down on fossil fuels being turned into carbon emissions and climate change." - Doctors For Healthy Trade NZ